NEXGEL Business Summary

NEXGEL, Inc. (NXGL) generates revenue through a hybrid business model centered on the manufacturing of high-water-content, electron-beam cross-linked hydrogels for the healthcare and consumer markets. The company operates through two primary segments: B2B Contract Manufacturing, providing specialized OEM solutions for medical device and cosmetic firms, and B2C Proprietary Products, which includes brands like Medigel, Kenkoderm, and the beauty-focused Silly George. Revenue is primarily transaction-based, derived from high-volume manufacturing contracts and direct-to-consumer sales via e-commerce and retail channels. NEXGEL competes with major players such as 3M (Medical Materials & Technologies), Scapa Healthcare (Mativ), and Avery Dennison Medical. It differentiates itself as a niche, high-tech specialist, leveraging its proprietary "clean" e-beam technology to offer superior biocompatibility and moisture management over the chemical-heavy adhesives produced by its larger, diversified competitors. The company is led by CEO Adam Levy, who has overseen NEXGEL’s transition from a private manufacturer to a public entity, leveraging his background in investment banking and corporate strategy to drive aggressive M&A activity and brand expansion. A key figure in the leadership structure is Executive Chairman Dr. Jerome Zeldis, whose tenure as the former Chief Medical Officer of Celgene provides the firm with significant clinical credibility and pharmaceutical industry expertise. The executive team is further supported by industry veterans in medical device commercialization and regulatory affairs. Notable institutional interest and the strategic guidance of Dr. Zeldis position NEXGEL as a medically-grounded innovator in the transdermal and wound care space, bridging the gap between traditional medical manufacturing and modern consumer wellness.